— Know what they know.
Not Investment Advice

DKSC OTC

Dakshidin Corporation
1W: +0.0% 1M: +33.3% 3M: +0.0% YTD: +100.0% 1Y: +300.0% 3Y: -20.0% 5Y: -86.7%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 54 · $1.8M mcap · Short 26% of daily vol

Balance Sheet Trends

Total Assets
$415K -21.9% ▼
5Y CAGR: +2.9%
Total Liabilities
$409K -19.5% ▼
5Y CAGR: +11.6%
Shareholders Equity
$7K -72.3% ▼
5Y CAGR: -44.0%
Cash & Investments
-$15 -100.3% ▼
Total Debt
$147K -0.0% ▼
5Y CAGR: +3.3%
Net Debt
$147K +4.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$2K$22K$10K$6K-$15
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$2K$22K$10K$6K-$15
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$0$0$0
Total Current Assets$77K$80K$210K$117K-$15
Property, Plant & Equip.$7K$7K$7K$7K$7K
Goodwill & Intangibles$0$408K$408K$408K$408K
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$408K$0$0$0$0
Total Non-Current Assets$415K$415K$415K$415K$415K
Total Assets$492K$495K$625K$532K$415K
— Liabilities —
Accounts Payable$135K$31K$33K$83K$24K
Short-Term Debt$0$0$125K$147K$147K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$208K$322K$276K$278K$238K
Total Current Liabilities$343K$354K$433K$508K$409K
Long-Term Debt$125K$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$125K$0$0$0$0
Total Liabilities$469K$354K$433K$508K$409K
— Equity —
Common Stock$1M$1M$1M$1M$3M
Retained Earnings-$1M-$1M-$1M-$1M-$2M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$24K$142K$192K$25K$7K
Total Liabilities & Equity$492K$495K$625K$532K$415K
— Key Metrics —
Total Debt$125K$0$125K$147K$147K
Net Debt$124K-$22K$115K$141K$147K
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms